Runcaciguat modified release - Bayer
Alternative Names: BAY 1101042; sGC Activator 1Latest Information Update: 08 Jul 2024
At a glance
- Originator Bayer
- Class Amines; Chlorobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Propionic acids; Small molecules; Urologics
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic retinopathy; Renal failure
Most Recent Events
- 22 Apr 2024 Bayer completes the phase II trial in Diabetic retinopathy in Germany, Poland, Portugal, US, Bulgaria, Latvia, Netherlands, Romania, Slovakia, Spain, Switzerland, UK (PO) (EudraCT2020-002333-15) (NCT04722991)
- 29 Apr 2022 Bayer completes the CONCORD phase II trial in Renal failure in Germany, Israel, Slovakia, Ukraine, Sweden, Poland, Italy, Finland, Bulgaria, Spain, Belgium, Austria, Denmark (PO) (NCT04507061)
- 13 Jul 2021 Bayer prematurely terminates its phase I trial in Renal failure (In Volunteers) in Germany (PO, Tablet) due to changes in the company's development strategy(NCT04820621) (EudraCT2020-005716-22)